Advertisement

Immunization in Adults

  • Richard B. Brown

Abstract

Over the past several years renewed emphasis has been placed on the role of the prevention of infections. Reasons for this include the documentation of cost effectiveness and cost savings from this strategy1,2 and the fact that several important infections such as tetanus, rabies, polio, and hepatitis B remain preventable but not specifically treatable. Indeed, much of the illness historically associated with childhood diseases is now seen in adults. For instance, for the year 1985, 100% of all cases of diphtheria, 93% of cases of tetanus, and almost 60% of cases of rubella occurred in patients over the age of 20.3 Similarly, only 20% of persons considered at high risk for complications of viral influenza and 10% of those at risk for pneumococcal infection have been vaccinated.3 Surveys demonstrate that at least 50% of persons over 60 years of age lack protective antibody to tetanus, and at least 40% lack antibody to diphtheria.3 It has been suggested that up to seven million adults are suceptible to measles, and as many as 11 million women of childbearing age are not immune to rubella.3

Keywords

Typhoid Fever Yellow Fever Immune Globulin Pneumococcal Vaccine Primary Immunization 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Williams JS, Sanders CR: Cost-effectiveness and cost–benefit analysis of vaccines. J Infect Dis 1981; 144: 486–493.CrossRefGoogle Scholar
  2. 2.
    Koplan JP, Schoenbaum SC, Weinstein ME, et al: Pertussis vaccine—an analysis of benefits, risks and costs. N Engl J Med 1979; 301: 906–911.PubMedCrossRefGoogle Scholar
  3. 3.
    Centers for Disease Control: Summary of the Second National Community Forum on Adult Immunization. Morbid Mortal Week Rep 1987; 36: 677–680.Google Scholar
  4. 4.
    Centers for Disease Control: General recommendations on immunization. Ann Intern Med 1983; 98 (part I): 615–622.Google Scholar
  5. 5.
    Committee on Immunizations, Council of Medical Societies, American College of Physicians: Guide for Adult Immunization. American College of Physicians, 1985.Google Scholar
  6. 6.
    Centers for Disease Control: Postexposure prophylaxis on hepatitis B. Morbid Mortal Week Rep 1984; 33: 285–290.Google Scholar
  7. 7.
    Centers for Disease Control: Rabies prevention—United States, 1984. Morbid Mortal Week Rep 1984; 33: 393–402.Google Scholar
  8. 8.
    Centers for Disease Control: Recommendations for protection against viral hepatitis. Morbid Mortal Week Rep 1985; 34: 313–335.Google Scholar
  9. 9.
    Centers for Disease Control: Suboptimal response to hepatitis B vaccine given by injection into the buttock. Morbid Mortal Week Rep 1985; 34: 105–113.Google Scholar
  10. 10.
    Hinman AR, Bart KJ, Orenstein WA: Immunization. In: Mandel GL, Douglas RG, Jr, Bennett JE, eds. Principles and Practice of Infectious Disease, ed 2. New York, John Wiley & Sons, 1986: 1688–1698.Google Scholar
  11. 11.
    Felsenfeld O, Wolf RH, Gyr K,: Simultaneous vaccination against cholera and yellow fever. Lancet 1973; 1: 457–458.PubMedCrossRefGoogle Scholar
  12. 12.
    Centers for Disease Control: Diphtheria, tetanus and pertussis: Guidelines for vaccine prophylaxis and other preventive measures. Morbid Mortal Week Rep 1985; 34: 405–426.Google Scholar
  13. 13.
    Immunization Practices Advisory Committees, Centers for Disease Control: Poliomyelitis prevention. Ann Intern Med 1982; 96: 630–634.CrossRefGoogle Scholar
  14. 14.
    Centers for Disease Control: Rubella vaccination during pregnancy-United States, 1971–1983. Morbid Mortal Week Rep 1984; 33: 365–373.Google Scholar
  15. 15.
    Fedson DS: Adult immunization: Protocols and problems. Hosp Pract 1986; 21: 143–158.Google Scholar
  16. 16.
    Centers for Disease Control: Health Information for International Travel, 1986. HHS Publication No. (CDC)86:8280, Washington, US Government Printing Office, 1986.Google Scholar
  17. 17.
    Acharya IL, Lowe CU, Thapa R,: Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. N Engl J Med 1987; 317: 1101–1104.CrossRefGoogle Scholar
  18. 18.
    Centers for Disease Control: Yellow fever vaccine. Morbid Mortal Week Rep 1984; 32: 679–688.Google Scholar
  19. 19.
    Snyder JD, Blake PA: Is cholera a problem for US travelers? JAMA 1982; 247: 2268–2269.Google Scholar
  20. 20.
    Centers for Disease Control: Lack of transmission of human immunodeficiency virus through Rho (D) immune globulin (human). Morbid Mortal Week Rep 1987; 36: 728–729.Google Scholar
  21. 21.
    Martin RR: Clostridium tetani (tetanus). In: Mandell GL, Douglas RG Jr, Bennett JE, eds. Principles and Practice of Infectious Disease,ed 2. New York, John Wiley & Sons, 1985:13551359.Google Scholar
  22. 22.
    Anderson LF, Nicholson KG, Tauxe RV,: Human rabies in the United States, 1960–1979: Epidemiology, diagnosis and prevention. Ann Intern Med 1984; 100: 728–735.PubMedCrossRefGoogle Scholar
  23. 23.
    Centers for Disease Control: Rabies prevention-United States, 1984. Morbid Mortal Week Rep 1984; 33: 393–407.Google Scholar
  24. 24.
    Centers for Disease Control: Systemic allergic reactions following immunization with human diploid cell rabies vaccine. Morbid Mortal Week Rep 1984; 33: 185–187.Google Scholar
  25. 25.
    Van Metre TE: Pneumococcal pneumonia treated with antibiotics: The prognostic significance of certain clinical findings. N Engl J Med 1954; 251: 1048–1052.CrossRefGoogle Scholar
  26. 26.
    Smit P, Oberholzer D, Hayden-Smith S,: Protective efficacy of pneumococcal polysaccharide vaccines. JAMA 1977; 238: 2613–2616.Google Scholar
  27. 27.
    Medical Letter: Pneumococcal vaccine. Med Lett 1978; 20: 13–14.Google Scholar
  28. 28.
    Bolan G, Broome CV, Facklam RR, et al: Pneumococcal vaccine efficacy in selected populations in the United States. Ann Intern Med 1986; 104: 1–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Simberkoff MS, Cross AP, Al-Ibrahim M,: Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration cooperative study. N Engl J Med 1986; 315: 318–327.CrossRefGoogle Scholar
  30. 30.
    Forrester HL, Jahnigen DW, LaForce FM: Inefficacy of pneumococcal vaccine in a high risk population. Am J Med 1987; 83: 425–430.PubMedCrossRefGoogle Scholar
  31. 31.
    Centers for Disease Control: Prevention and control of influenza. Recommendations of the Immunization Practices Advisory Committee. Ann Intern Med 1987; 107: 521–525.CrossRefGoogle Scholar
  32. 32.
    Lipsky BA, Pecoraro RE, Roben NJ,: Influenza vaccination and warfarin anticoagulation. Ann Intern Med 1984; 100: 835–837.PubMedCrossRefGoogle Scholar
  33. 33.
    Dienstag JL, Ryan DM: Occupational exposure to hepatitis B virus personnel: Infection or immunization ? Am J Epidemiol 1982; 115: 26–39.PubMedGoogle Scholar
  34. 34.
    Szmuness W, Stevens CE, Harley EJ,: Hepatitis B vaccine. Demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980; 303: 833–841.PubMedCrossRefGoogle Scholar
  35. 35.
    Merck Sharp & Dohme: Hepatitis B Vaccine [Recombinant, MSD] package insert. West Point, PA, Merck Sharp & Dohme, undated.Google Scholar
  36. 36.
    Zachoval R, Jilg W, Corbeer B,: Passive/active immunization against hepatitis B. J Infect Dis 1984; 150: 112–117.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1988

Authors and Affiliations

  • Richard B. Brown

There are no affiliations available

Personalised recommendations